June 17th 2025
FDA updates talazoparib and enzalutamide labeling, confirming survival benefits for HRR-mutated mCRPC, while excluding non-HRR patients.
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow
View More
Evaluating Patient-Reported Outcomes in MAGNITUDE Trial for mCRPC
April 4th 2024Kim N. Chi, MD, FRCPC, discusses the significance of the phase 3 MAGNITUDE trial, including its evaluation on patient-reported outcomes, in patients with BRCA1/2-altered metastatic castration-resistant prostate cancer.
Watch
Risk/Benefits of Managing AEs with Combination Therapy
March 26th 2024Dr. Motzer discusses the risk/benefits considerations that guide decisions around continuing combination therapy with dose adjustments or stopping one agent when moderate AEs like diarrhea or liver enzyme elevations emerge in nccRCC patients on IO plus TKI regimens.
Watch
Niraparib With Abiraterone Boosts Survival in BRCA-Mutated Prostate Cancer
March 24th 2024Kim N. Chi, MD, FRCPC, discusses results from the MAGNITUDE trial, including those on survival and patient-reported outcomes in patients with BRCA-positive metastatic castration-resistant prostate cancer receiving niraparib plus abiraterone acetate and prednisone.
Watch
Real-World Survival Analysis of Apalutamide vs Enzalutamide in mCSPC
February 14th 2024Neal Shore, MD, FACS, discusses a study aimed to investigate the real-world survival outcomes of men with metastatic castration-sensitive prostate cancer treated with either apalutamide or enzalutamide in the United States.
Watch